N-terminally chemically modified protein compositions and methods
View Patent ↗Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.
1. An antiviral, pegylated consensus interferon.
2. The antiviral, pegylated consensus interferon of claim 1 that is an anti-hepatitis viral, pegylated consensus interferon.
3. The antiviral, pegylated consensus interferon of claim 1 that is an antihepatitis C viral, pegylated consensus interferon.
4. The anti-hepatitis C viral, pegylated consensus interferon of claim 3 wherein said consensus interferon is selected from from the group consisting of IFN-con 1 , IFN-con 2 , and IFN-con 3 .
5. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con 1 .
6. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con 2 .
7. The anti-hepatitis C viral, pegylated consensus interferon of claim 4 wherein said consensus interferon is IFN-con 3 .
8. The antiviral, pegylated consensus interferon of claim 1 that is an antiviral, monopegylated consensus interferon.
9. N-terminally pegylated consensus interferon.
10. N-terminally pegylated consensus interferon of claim 9 wherein said consensus interferon is selected from the group consisting of IFN-con 1 , IFN-con 2 , and IFN-con 3 .
11. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con 1 .
12. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con 2 .
13. N-terminally pegylated consensus interferon of claim 10 wherein said consensus interferon is IFN-con 3 .
14. N-terminally monopegylated consensus interferon.
15. A pharmaceutical composition comprising:
(a) antiviral, pegylated consensus interferon; and
(b) a pharmaceutically acceptable diluent, adjuvant or carrier.
16. The pharmaceutical composition of claim 15 that is essentially free of consensus interferon PEGylated at sites other than the N-terminus.
17. The pharmaceutical composition of claim 15 werein said consensus interferon is selected from the group consisting of IFN-con 1 , IFN-con 2 , and IFN-con 3 .
18. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con 1 .
19. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con 2 .
20. The pharmaceutical composition of claim 17 wherein said consensus interferon is IFN-con 3 .
21. The pharmaceutical composition of claim 15 wherein said consensus interferon is monopegylated.
22. A pharmaceutical composition comprising:
(a) N-terminally pegylated consensus interferon; and
(b) a pharmaceutically acceptable diluent, adjuvant or carrier.
23. The pharmaceutical composition of claim 22 that is essentially free of consensus interferon PEGylated at sites other than the N-terminus.
24. The pharmaceutical composition of claim 22 wherein said consensus interferon is selected from the group consisting of IFN-con 1 , IFN-con 2 , and IFN-con 3 .
25. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con 1 .
26. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con 2 .
27. The pharmaceutical composition of claim 24 wherein said consensus interferon is IFN-con 3 .
28. The pharmaceutical composition of claim 25 wherein said consensus interferon is monopegylated.